Results: Firstly, using a combination of published crystal structures and in-house data, we demonstrated that the binding site utilized by all of the DPP-4 inhibitors assessed was the same as that used by neuropeptide Y, supporting the hypothesis that DPP-4 inhibitors are able to competitively inhibit endogenous substrates for the enzyme.
| INTRODUCTION
Dipeptidyl peptidase 4 (DPP-4) inhibitors are effective antihyperglycaemic agents by virtue of their ability to inhibit the breakdown of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) . 1 This results in increased plasma levels of the intact and, thus, biologically active form of both incretin hormones, which results in an improvement of glycaemic control primarily via augmentation of glucose-stimulated insulin secretion and inhibition of glucagon release by the beta and alpha cells of the pancreas, respectively. ficacy. 4 To address this, we undertook a direct comparison of five commonly used DPP-4 inhibitors (together with a pharmacologically active metabolite of one of them) to assess their molecular interactions with the DPP-4 enzyme in comparison with a known DPP-4 substrate (a fragment of neuropeptide Y, tNPY) and to examine their activity using standardized enzyme inhibition assays in vitro. We also used an acute oral glucose tolerance test (OGTT) in the mouse in vivo to enable a direct head-to-head comparison of the antihyperglycaemic and enzyme inhibitory properties of each inhibitor to be made. We used human recombinant DPP-4 for the X-ray crystallography and murine-based assays for measuring enzyme inhibition and antihyperglycaemic effects. To address some aspects of the potential impact of species differences, we compared the inhibitory potency of the inhibitors in assays using human-and murine-derived enzymes.
In a previous study, Nabeno et al 5 assigned some of the then existing DPP-4 inhibitors into three classes, based upon their binding to the core S1, S2 sites, to the S1' and S2' sites, and to a further "S2 extensive subsite" within the target enzyme. They suggested that differences in duration of action and selectivity for DPP-4 binding versus other related enzymes may result from differences in binding to these specific binding sites. However, it remained unknown as to whether such differences between the inhibitors with respect to their DPP-4 binding characteristics might result in differences in biological efficacy (ie, glucose lowering). As soluble DPP-4 circulates in plasma, measurement of murine plasma DPP-4 activity in treated animals provides an index of in vivo target engagement and acute pharmacodynamics for the various inhibitors and permits assessment of the correlation between the extent of plasma DPP-4 inhibition ex vivo and the corresponding glucose-lowering efficacy in vivo.
Of note, not all DPP-4 inhibitors are metabolically stable in vivo. 6 Both vildagliptin and saxagliptin are known to be metabolized extensively, 7, 8 with saxagliptin forming an active metabolite (saxagliptin M2) in vivo. 8 Hence, we also included saxagliptin M2 for in vitro potency measurement and enzyme binding assessment.
| RESEARCH DESIGN AND METHODS

| Materials and methods
| Reagents
Alogliptin, linagliptin, saxagliptin, saxagliptin M2 (active metabolite), sitagliptin and vildagliptin were synthesized in house. 
| Animals
| Structural studies
The soluble domain of human DPP-4 (residues 39-766) was prepared as described. 9 The structures for tNPY, sitagliptin, alogliptin, saxagliptin and linagliptin complexes with DPP-4 have been previously reported. [10] [11] [12] [13] [14] To obtain the structures of the correspond- gand was fitted to the available difference electron density using AFITT, 15 and the structures were refined against all available data using REFMA. 16 Coordinates have been deposited with the Protein Data Bank, accession code 6B1O and 6B1E for the saxagliptin M2
and the vildagliptin complex, respectively.
In vitro potency assays for inhibition of DPP-4
Briefly, human DPP-4 activity was assayed in vitro as described previ- Inhibitory potencies for murine DPP-4 were determined by measuring murine plasma DPP-4 activity in a CF assay containing 2% mouse plasma, 100 mmol/L HEPES, pH 7.5, 0.1% BSA and 5 μmol/L GlyPro-AMC as substrate at 37°C for 5 minutes (excitation/emission: 360/460 nm). The inhibitory potency (IC 50 ) was calculated for both human and mouse DPP-4 using a method described previously. 17 Summary statistics were calculated as the arithmetic mean and the standard deviation.
| Oral glucose tolerance test (OGTT) in lean mice
Male C57/Bl6N mice (n = 6-8/group) were randomly assigned to treatment groups and fasted overnight (~18-21 hours). Baseline The blood glucose excursion profile from t = 0 to t = 120 minutes was used to integrate an area under the curve (AUC) and to calculate an average plasma glucose excursion (Cav = AUC/120 minutes) for each treatment.
| Measurement of murine plasma DPP-4 activity ex vivo
Male C57/Bl6N mice (n = 20-28/group) were randomly assigned to treatment or vehicle groups and fasted overnight (~18-21 hours). 
| Relationship between plasma DPP-4 inhibition ex vivo and acute glucose lowering (OGTT) in lean mice
Briefly, a linear mixed-effects mathematical model was developed relating the observed plasma DPP-4 inhibition data collected 70 minutes postdose (10 minutes after dextrose challenge) to the observed baseline average plasma glucose excursion (Cav) OGTT data in the parallel cohort for the pooled data set of all five DPP-4 inhibitors. To determine whether the relationship between acute pharmacodynamics and efficacy might substantially vary by inhibitor, an additional factor for specific inhibitor was also tested in the mixed-effects model for statistical significance (prespecified P value: .05), using Kenward 
| RESULTS
| Comparison of DPP-4 inhibitor binding interactions and inhibitory potencies
| In vitro and ex vivo potencies of DPP-4 inhibitors
The inhibitory activities of the different compounds were determined against both human and murine DPP-4 in vitro and are shown in Table 1 . As shown, the inhibitory potency (IC 50 ) was highly consistent between species and spanned a range in human from 0.14 nmol/L for linagliptin to 34 nmol/L for vildagliptin.
| Comparison of acute antihyperglycaemic activity in lean mice
All of the compounds dose-dependently inhibited plasma DPP-4 activity ( Figure 3 ) with maximal plasma DPP-4 inhibition levels of ~80%- 
| DISCUSSION
The present study is a direct comparison of the acute pharmacological The use of human enzyme for the binding studies and murine-based assays for the in vivo work is justified due to the highly homologous human and murine structures of the DPP-4 enzyme and the similar potencies of the various DPP-4 inhibitors using assays from the two species. 24 The inhibitory potency data shown in Table 1 illustrate that the relatively high degree of sequence identity (85%) and homology (92%) are reflected by broadly similar potency values when comparing the human and murine enzyme. Regarding the values of potency per se, the results obtained in this study are broadly in agreement with values cited elsewhere. 6 In this context, it is also important to note that despite the observed differences in inhibitory potencies across the chemically diverse inhibitors in vitro (Table 1) 
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